Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT03533582	Phase II	Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Carboplatin + Cisplatin + Doxorubicin + Etoposide Carboplatin + Cisplatin + Doxorubicin + Irinotecan + Vincristine Sulfate Cisplatin Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin	Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery	Active, not recruiting	USA \| NZL \| CAN \| AUS	2
NCT03213665	Phase II	Tazemetostat	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA	1
NCT04266912	Phase Ib/II	Avelumab + Berzosertib	Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors	Active, not recruiting	USA	0
NCT03274258	Phase II	Ipilimumab + Nivolumab	Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma	Active, not recruiting	USA	0
NCT04965753	Phase I	FHD-609	FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors	Terminated	USA \| ITA \| FRA \| ESP	0
NCT05715281	Phase II	Atezolizumab + Tiragolumab	Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial	Recruiting	USA	0
NCT04416568	Phase II	Ipilimumab + Nivolumab	Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers	Recruiting	USA	0
NCT02114229	Phase II	Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Alisertib Alisertib + Carboplatin + Cyclophosphamide + Vincristine Sulfate Cyclophosphamide + Topotecan Alisertib + Carboplatin + Cyclophosphamide + Etoposide Carboplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Alisertib + Cisplatin + Cyclophosphamide + Vincristine Sulfate	Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT)	Active, not recruiting	USA	0
NCT06444880	Phase II	Cemiplimab + REGN4018 REGN4018	Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies	Recruiting	USA	0
NCT04204941	Phase III	Doxorubicin Doxorubicin + Tazemetostat	Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma	Recruiting	USA \| GBR \| CAN	1
NCT05407441	Phase Ib/II	Ipilimumab + Nivolumab + Tazemetostat	Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors	Recruiting	USA	0
NCT02601937	Phase I	Tazemetostat	A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma	Completed	USA \| NLD \| ITA \| GBR \| FRA \| DNK \| DEU \| CAN \| AUS	0
NCT05355753	Phase Ib/II	CFT8634	A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors	Terminated	USA	0
NCT02601950	Phase II	Tazemetostat	A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma	Completed	USA \| ITA \| GBR \| FRA \| DEU \| CAN \| BEL \| AUS	1
NCT05286801	Phase Ib/II	Atezolizumab + Tiragolumab	Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	Recruiting	USA \| CAN \| AUS	0
NCT03654716	Phase I	ALRN-6924 + Cytarabine ALRN-6924	Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer	Completed	USA	0
NCT03155620	Phase II	Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Recruiting	USA \| CAN \| AUS	1
NCT03375307	Phase II	Olaparib	Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes	Recruiting	USA	0
NCT03587662	Phase II	Gemcitabine + Ixazomib Doxorubicin + Gemcitabine + Ixazomib	Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer	Active, not recruiting	USA	0
NCT05347212	Phase II	Nivolumab + Relatlimab	Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla	Active, not recruiting	USA	0

Gene Detail

Contact

Filtering

Sorting